These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 20407889

  • 1. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.
    Polyzos SA, Kountouras J, Anastasilakis AD, Litsas I, Kita M, Arsos G, Moralidis E, Terpos E.
    Osteoporos Int; 2011 Jan; 22(1):363-7. PubMed ID: 20407889
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis.
    Jiang Y, Fu Y, Xing XP, Li M, Wang O, Xia WB, Meng XW.
    Eur J Med Res; 2015 Aug 22; 20(1):68. PubMed ID: 26297149
    [Abstract] [Full Text] [Related]

  • 3. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Aug 22; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 4. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    J Bone Miner Metab; 2010 Nov 22; 28(6):706-12. PubMed ID: 20533067
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 22; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The use of zoledronic acid for Paget's disease of bone.
    Maricic M.
    Curr Osteoporos Rep; 2006 Mar 22; 4(1):40-4. PubMed ID: 16527007
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ, Sternon J.
    Rev Med Brux; 2005 Mar 22; 26(6):513-7. PubMed ID: 16454155
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
    Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M.
    J Bone Miner Metab; 2008 Mar 22; 26(6):635-41. PubMed ID: 18979164
    [Abstract] [Full Text] [Related]

  • 13. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
    Grados D, Martínez-Morillo M, Holgado S, Erra A.
    Med Clin (Barc); 2014 May 20; 142(10):469-70. PubMed ID: 24120108
    [No Abstract] [Full Text] [Related]

  • 14. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A, Rotés Sala D, Almirall Bernabé M, Carbonell Abelló J.
    Med Clin (Barc); 2006 Oct 28; 127(16):635-6. PubMed ID: 17145033
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 16. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA.
    Clin Rheumatol; 2011 Jan 01; 30(1):149-50. PubMed ID: 21053036
    [No Abstract] [Full Text] [Related]

  • 17. Drug-induced hepatotoxicity linked to zoledronic acid in the treatment of an elderly man with primary osteoporosis.
    Chen W, Zhu M.
    Int J Clin Pharmacol Ther; 2021 Nov 01; 59(11):721-724. PubMed ID: 34423770
    [Abstract] [Full Text] [Related]

  • 18. Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.
    Ferraz-de-Souza B, Martin RM, Correa PH.
    J Bone Miner Metab; 2013 May 01; 31(3):360-5. PubMed ID: 23076294
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP, Manicourt DH.
    Expert Opin Pharmacother; 2007 Nov 01; 8(16):2863-9. PubMed ID: 17956205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.